Altient

Altient is a clinical-stage radiopharmaceutical company launched in 2024 as a dedicated therapeutic entity of NorthStar Medical Radioisotopes. The company focuses on the development of targeted radiotherapies for cancer, utilizing high-purity alpha-emitting and beta-emitting isotopes such as Actinium-225 and Copper-67. Altient's strategy involves combining proprietary targeting molecules with its parent company's established isotope production infrastructure to ensure a reliable supply chain for next-generation treatments. Its pipeline includes programs targeting the urokinase plasminogen activator receptor (uPAR) and prostate-specific membrane antigen (PSMA) for various solid tumors. Headquartered in Beloit, Wisconsin, Altient aims to advance precision oncology through the integration of diagnostic and therapeutic radiopharmaceuticals.